Display options
Cite
Al-Anazi KA, Al-Jasser AM. Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation. Front Oncol. 2014;4:232doi: 10.3389/fonc.2014.00232.
Al-Anazi, K. A., & Al-Jasser, A. M. (2014). Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation. Frontiers in oncology, 4232. https://doi.org/10.3389/fonc.2014.00232
Al-Anazi, Khalid Ahmed, and Al-Jasser, Asma M. "Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation." Frontiers in oncology vol. 4 (2014): 232. doi: https://doi.org/10.3389/fonc.2014.00232
Al-Anazi KA, Al-Jasser AM. Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation. Front Oncol. 2014 Aug 25;4:232. doi: 10.3389/fonc.2014.00232. eCollection 2014. PMID: 25202682; PMCID: PMC4142553.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2014 Aug 25;4:232. doi: 10.3389/fonc.2014.00232. eCollection 2014.

Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation.

Frontiers in oncology

Khalid Ahmed Al-Anazi, Asma M Al-Jasser

Affiliations

  1. Section of Adult Hematology and Oncology, Department of Medicine, College of Medicine, King Khalid University Hospital, King Saud University , Riyadh , Saudi Arabia.
  2. Central Laboratory, Ministry of Health , Riyadh , Saudi Arabia.

PMID: 25202682 PMCID: PMC4142553 DOI: 10.3389/fonc.2014.00232

Abstract

Stenotrophomonas maltophilia (S. maltophilia) is a globally emerging Gram-negative bacillus that is widely spread in environment and hospital equipment. Recently, the incidence of infections caused by this organism has increased, particularly in patients with hematological malignancy and in recipients of hematopoietic stem cell transplantation (HSCT) having neutropenia, mucositis, diarrhea, central venous catheters or graft versus host disease and receiving intensive cytotoxic chemotherapy, immunosuppressive therapy, or broad-spectrum antibiotics. The spectrum of infections in HSCT recipients includes pneumonia, urinary tract and surgical site infection, peritonitis, bacteremia, septic shock, and infection of indwelling medical devices. The organism exhibits intrinsic resistance to many classes of antibiotics including carbapenems, aminoglycosides, most of the third-generation cephalosporins, and other β-lactams. Despite the increasingly reported drug resistance, trimethoprim-sulfamethoxazole is still the drug of choice. However, the organism is still susceptible to ticarcillin-clavulanic acid, tigecycline, fluoroquinolones, polymyxin-B, and rifampicin. Genetic factors play a significant role not only in evolution of drug resistance but also in virulence of the organism. The outcome of patients having S. maltophilia infections can be improved by: using various combinations of novel therapeutic agents and aerosolized aminoglycosides or colistin, prompt administration of in vitro active antibiotics, removal of possible sources of infection such as infected indwelling intravascular catheters, and application of strict infection control measures.

Keywords: Stenotrophomonas maltophilia; bacteremia; drug resistance; hematopoietic stem cell transplantation; neutropenia

References

  1. Crit Care. 2006;10(5):R143 - PubMed
  2. J Antimicrob Chemother. 2013 May;68 Suppl 1:i7-22 - PubMed
  3. J Antimicrob Chemother. 2007 Jun;59(6):1223-9 - PubMed
  4. Ann Pharmacother. 2010 Oct;44(10):1665-8 - PubMed
  5. J Clin Microbiol. 2010 Jun;48(6):2030-6 - PubMed
  6. Biomed Res Int. 2013;2013:723680 - PubMed
  7. Ann Clin Microbiol Antimicrob. 2006 Sep 18;5:23 - PubMed
  8. Diagn Microbiol Infect Dis. 2002 Nov;44(3):259-63 - PubMed
  9. Springerplus. 2013 May 07;2(1):207 - PubMed
  10. Biomed Pharmacother. 2005 Oct;59(9):511-6 - PubMed
  11. J Antimicrob Chemother. 2011 May;66(5):1024-8 - PubMed
  12. J Microbiol Immunol Infect. 2004 Dec;37(6):359-65 - PubMed
  13. Eur Respir J. 2007 Dec;30(6):1234-5 - PubMed
  14. Leuk Lymphoma. 2004 Aug;45(8):1637-41 - PubMed
  15. Front Immunol. 2012 Oct 05;3:309 - PubMed
  16. Antimicrob Agents Chemother. 2004 Jan;48(1):151-60 - PubMed
  17. Clin Infect Dis. 2012 Mar 1;54(5):670-80 - PubMed
  18. Int J Antimicrob Agents. 2011 Mar;37(3):230-4 - PubMed
  19. Antimicrob Agents Chemother. 2012 Jun;56(6):3080-5 - PubMed
  20. J Infect Chemother. 2010 Oct;16(5):322-8 - PubMed
  21. Transpl Infect Dis. 2012 Aug;14(4):355-63 - PubMed
  22. Kansenshogaku Zasshi. 2013 Sep;87(5):596-602 - PubMed
  23. Clin Infect Dis. 2000 Sep;31(3):705-11 - PubMed
  24. Clin Infect Dis. 2000 Jan;30(1):195-7 - PubMed
  25. Eur J Cancer. 2009 Sep;45(14):2462-72 - PubMed
  26. Diagn Microbiol Infect Dis. 2008 Feb;60(2):205-10 - PubMed
  27. Discov Med. 2011 Dec;12(67):461-70 - PubMed
  28. Bone Marrow Transplant. 2010 Jun;45(6):1109-10 - PubMed
  29. Pharmacotherapy. 1997 Mar-Apr;17(2):293-301 - PubMed
  30. Expert Rev Anti Infect Ther. 2014 Jan;12(1):1-4 - PubMed
  31. J Microbiol Immunol Infect. 2004 Dec;37(6):350-8 - PubMed
  32. Infect Immun. 2003 Jun;71(6):3068-75 - PubMed
  33. Ann Intensive Care. 2014 Apr 28;4:13 - PubMed
  34. Clin Infect Dis. 2001 May 15;32 Suppl 2:S104-13 - PubMed
  35. J Antimicrob Chemother. 2003 Apr;51(4):803-11 - PubMed
  36. PLoS One. 2012;7(5):e37375 - PubMed
  37. Clin Transplant. 2014 Jun;28(6):656-61 - PubMed
  38. Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):229-37 - PubMed
  39. J Infect. 2012 Apr;64(4):391-8 - PubMed
  40. Int J Infect Dis. 2011 May;15(5):e326-31 - PubMed
  41. J Antimicrob Chemother. 2001 Jul;48(1):152-4 - PubMed
  42. J Antimicrob Chemother. 2011 Apr;66(4):834-9 - PubMed
  43. Korean J Lab Med. 2010 Jun;30(3):295-300 - PubMed
  44. Clin Infect Dis. 2002 Jun 15;34(12):1653-6 - PubMed
  45. Expert Rev Anti Infect Ther. 2011 Apr;9(4):471-88 - PubMed
  46. Bone Marrow Transplant. 2007 Jul;40(1):71-8 - PubMed
  47. Curr Top Med Chem. 2010;10(18):1848-57 - PubMed
  48. Blood. 2012 Aug 30;120(9):1791-800 - PubMed
  49. Antimicrob Agents Chemother. 2014;58(4):2405-8 - PubMed
  50. J Antimicrob Chemother. 2014 Sep;69(9):2326-36 - PubMed
  51. Can J Infect Dis Med Microbiol. 2012 Winter;23(4):165-9 - PubMed
  52. J Hosp Infect. 2008 Oct;70(2):101-8 - PubMed
  53. J Infect Dis. 2012 Jun;205(11):1709-18 - PubMed
  54. Recent Pat Antiinfect Drug Discov. 2013 Apr;8(1):68-83 - PubMed
  55. Ann Hematol. 2014 Jun;93(6):901-11 - PubMed
  56. PLoS Pathog. 2011 Jun;7(6):e1002103 - PubMed
  57. J Hosp Infect. 2012 Jun;81(2):114-8 - PubMed
  58. BMC Infect Dis. 2013 Apr 05;13:166 - PubMed
  59. Infect Control Hosp Epidemiol. 2003 Apr;24(4):269-74 - PubMed
  60. Int J Infect Dis. 2012 Aug;16(8):e603-7 - PubMed
  61. Cancer. 2006 May 1;106(9):1967-73 - PubMed
  62. Antimicrob Agents Chemother. 1997 May;41(5):1140-2 - PubMed
  63. Transpl Infect Dis. 2012 Feb;14(1):40-8 - PubMed
  64. Kansenshogaku Zasshi. 2012 May;86(3):300-5 - PubMed
  65. Appl Environ Microbiol. 2010 Mar;76(6):1746-58 - PubMed
  66. Infect Control Hosp Epidemiol. 2008 Feb;29(2):125-30 - PubMed
  67. J Clin Microbiol. 2010 Oct;48(10):3510-6 - PubMed
  68. Emerg Infect Dis. 2007 Apr;13(4):559-65 - PubMed
  69. Antimicrob Agents Chemother. 2001 Dec;45(12):3497-503 - PubMed
  70. Clin Imaging. 2013 Jul-Aug;37(4):669-79 - PubMed
  71. Antimicrob Agents Chemother. 2005 Sep;49(9):3980-1 - PubMed
  72. Antimicrob Agents Chemother. 2014;58(1):176-82 - PubMed
  73. Bone Marrow Transplant. 2013 Jan;48(1):74-9 - PubMed
  74. J Clin Oncol. 1999 Mar;17(3):796-805 - PubMed
  75. Mem Inst Oswaldo Cruz. 2013 May;108(3): - PubMed
  76. Bone Marrow Transplant. 2010 May;45(5):945-50 - PubMed
  77. Antimicrob Agents Chemother. 2002 Feb;46(2):333-43 - PubMed
  78. Bone Marrow Transplant. 2006 Nov;38(10):693-8 - PubMed
  79. Recent Pat Antiinfect Drug Discov. 2009 Jan;4(1):37-50 - PubMed
  80. AJR Am J Roentgenol. 1997 Nov;169(5):1347-53 - PubMed
  81. Clin Infect Dis. 2009 Jul 1;49(1):1-45 - PubMed
  82. Clin Microbiol Rev. 1998 Jan;11(1):57-80 - PubMed
  83. Antimicrob Agents Chemother. 2000 Jul;44(7):1778-82 - PubMed
  84. J Antimicrob Chemother. 2010 Mar;65(3):483-9 - PubMed
  85. J Ayub Med Coll Abbottabad. 2012 Apr-Jun;24(2):30-3 - PubMed
  86. Semin Respir Crit Care Med. 2007 Dec;28(6):672-7 - PubMed
  87. Int J Antimicrob Agents. 2009 Sep;34(3):260-4 - PubMed
  88. Microbiol Mol Biol Rev. 2006 Jun;70(2):296-316 - PubMed
  89. Infection. 2010 Jun;38(3):211-5 - PubMed
  90. Mikrobiyol Bul. 2005 Jan;39(1):25-33 - PubMed
  91. J Clin Microbiol. 2009 Aug;47(8):2405-10 - PubMed
  92. J Korean Med Sci. 2013 Jan;28(1):62-6 - PubMed
  93. J Med Microbiol. 2013 May;62(Pt 5):748-753 - PubMed
  94. Biomed Res Int. 2013;2013:392058 - PubMed
  95. J Microbiol Immunol Infect. 2006 Apr;39(2):144-9 - PubMed
  96. Infection. 2013 Oct;41(5):991-7 - PubMed
  97. Genome Announc. 2013 May 02;1(3): - PubMed
  98. J Antimicrob Chemother. 2012 Jul;67(7):1701-5 - PubMed
  99. J Bras Pneumol. 2009 May;35(5):431-5 - PubMed
  100. Int J Med Microbiol. 2005 Apr;295(1):47-55 - PubMed
  101. Genome Biol. 2008 Apr 17;9(4):R74 - PubMed
  102. Antimicrob Agents Chemother. 2011 Dec;55(12):5826-33 - PubMed
  103. Clin Microbiol Rev. 2012 Jan;25(1):2-41 - PubMed
  104. Infect Control Hosp Epidemiol. 1999 Nov;20(11):756-8 - PubMed
  105. Lancet Infect Dis. 2009 May;9(5):312-23 - PubMed
  106. J Formos Med Assoc. 2002 Jul;101(7):495-501 - PubMed
  107. J Antimicrob Chemother. 2008 Nov;62(5):889-94 - PubMed
  108. Scand J Infect Dis. 2013 Apr;45(4):265-70 - PubMed
  109. Multidiscip Respir Med. 2013 Feb 18;8(1):14 - PubMed
  110. Clin Infect Dis. 2003 May 1;36(9):1162-70 - PubMed
  111. Clin Infect Dis. 2002 Jan 15;34(2):177-83 - PubMed
  112. J Antimicrob Chemother. 2013 Sep;68(9):1987-93 - PubMed
  113. Antimicrob Agents Chemother. 2014;58(1):581-3 - PubMed
  114. Haematologica. 2013 Dec;98(12):1836-47 - PubMed
  115. Clin Infect Dis. 2002 May 15;34(10):1362-8 - PubMed
  116. Infect Control Hosp Epidemiol. 2004 Aug;25(8):646-9 - PubMed
  117. Clin Infect Dis. 2007 Dec 15;45(12):1602-9 - PubMed
  118. Bone Marrow Transplant. 2010 Apr;45(4):647-55 - PubMed

Publication Types